Nature Communications publishes Bluestar Genomics’ technology for cancer detection study
Bluestar Genomics, an innovative company leading the development of next-generation epigenomic approaches to early cancer detection, announced today the publication of study results in the peer-reviewed journal Nature Communications. The study demonstrates the power of the company’s platform to detect pancreatic cancer in its early stages, addressing the unmet need of more than 60,000 patients…